低收入和中等收入国家病毒性肝炎预防和治疗的创新供资来源:圆桌会议报告。

Hepatology, medicine and policy Pub Date : 2016-12-16 eCollection Date: 2016-01-01 DOI:10.1186/s41124-016-0022-8
David FitzSimons, Greet Hendrickx, Johannes Hallauer, Heidi Larson, Daniel Lavanchy, Ina Lodewyckx, Daniel Shouval, John Ward, Pierre Van Damme
{"title":"低收入和中等收入国家病毒性肝炎预防和治疗的创新供资来源:圆桌会议报告。","authors":"David FitzSimons,&nbsp;Greet Hendrickx,&nbsp;Johannes Hallauer,&nbsp;Heidi Larson,&nbsp;Daniel Lavanchy,&nbsp;Ina Lodewyckx,&nbsp;Daniel Shouval,&nbsp;John Ward,&nbsp;Pierre Van Damme","doi":"10.1186/s41124-016-0022-8","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatitis B is preventable and hepatitis C is treatable even if still at a high cost; most people who are infected with hepatitis B or C virus have not been screened yet and are unaware of their infections; and most countries, especially developing countries, do not have a national plan to prevent and control viral hepatitis. The advent of effective new treatments for hepatitis C has been an agent of change, allowing consideration of the feasibility of eliminating that disease and accelerating the control of viral hepatitis generally. These facts inspired the Viral Hepatitis Prevention Board (VHPB) to organize a meeting in London (8-9 June 2015) on innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries. The main focus of the meeting was to provide an overview of current health systems controlling viral hepatitis in low- and middle-income countries (LMICs); to identify ways to increase political commitment and financial sustainability of viral hepatitis prevention and control programmes in such countries; to identify potential funders and explore new funding mechanisms; to discuss lessons learnt about funding other disease programmes; to investigate how to convince and motivate decision-makers to fund viral hepatitis programmes in LMICs; to provide options for improving access to affordable screening and treatment of viral hepatitis in LMICs; and to list the commitments required for funding by donors, including governments, bilateral and multilateral organizations, non-traditional donors, development banks, foundations, and commercial financial institutions. To improve viral hepatitis prevention and treatment in LMICs participating hepatitis and financing experts identified the most urgent needs. Data on burden of disease must be improved. Comprehensive hepatitis policies and strategies should be drafted and implemented, and existing strategies and policies improved to increase access to treatment and prevention. Strong political will and leadership should be generated, potential partners identified and partnerships created. Potential funders and funding mechanisms have to be researched. The outcome of this meeting was integrated in a VHPB project to investigate creative financing solutions to expand access to and provision of screening and other preventive services, treatment and care of hepatitis B and C in LMICs. The report is available on www.vhpb.org.</p>","PeriodicalId":91692,"journal":{"name":"Hepatology, medicine and policy","volume":"1 ","pages":"16"},"PeriodicalIF":0.0000,"publicationDate":"2016-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s41124-016-0022-8","citationCount":"9","resultStr":"{\"title\":\"Innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries: a roundtable meeting report.\",\"authors\":\"David FitzSimons,&nbsp;Greet Hendrickx,&nbsp;Johannes Hallauer,&nbsp;Heidi Larson,&nbsp;Daniel Lavanchy,&nbsp;Ina Lodewyckx,&nbsp;Daniel Shouval,&nbsp;John Ward,&nbsp;Pierre Van Damme\",\"doi\":\"10.1186/s41124-016-0022-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hepatitis B is preventable and hepatitis C is treatable even if still at a high cost; most people who are infected with hepatitis B or C virus have not been screened yet and are unaware of their infections; and most countries, especially developing countries, do not have a national plan to prevent and control viral hepatitis. The advent of effective new treatments for hepatitis C has been an agent of change, allowing consideration of the feasibility of eliminating that disease and accelerating the control of viral hepatitis generally. These facts inspired the Viral Hepatitis Prevention Board (VHPB) to organize a meeting in London (8-9 June 2015) on innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries. The main focus of the meeting was to provide an overview of current health systems controlling viral hepatitis in low- and middle-income countries (LMICs); to identify ways to increase political commitment and financial sustainability of viral hepatitis prevention and control programmes in such countries; to identify potential funders and explore new funding mechanisms; to discuss lessons learnt about funding other disease programmes; to investigate how to convince and motivate decision-makers to fund viral hepatitis programmes in LMICs; to provide options for improving access to affordable screening and treatment of viral hepatitis in LMICs; and to list the commitments required for funding by donors, including governments, bilateral and multilateral organizations, non-traditional donors, development banks, foundations, and commercial financial institutions. To improve viral hepatitis prevention and treatment in LMICs participating hepatitis and financing experts identified the most urgent needs. Data on burden of disease must be improved. Comprehensive hepatitis policies and strategies should be drafted and implemented, and existing strategies and policies improved to increase access to treatment and prevention. Strong political will and leadership should be generated, potential partners identified and partnerships created. Potential funders and funding mechanisms have to be researched. The outcome of this meeting was integrated in a VHPB project to investigate creative financing solutions to expand access to and provision of screening and other preventive services, treatment and care of hepatitis B and C in LMICs. The report is available on www.vhpb.org.</p>\",\"PeriodicalId\":91692,\"journal\":{\"name\":\"Hepatology, medicine and policy\",\"volume\":\"1 \",\"pages\":\"16\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-12-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/s41124-016-0022-8\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatology, medicine and policy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s41124-016-0022-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2016/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology, medicine and policy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41124-016-0022-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

摘要

乙型肝炎是可以预防的,丙型肝炎是可以治疗的,尽管费用仍然很高;大多数乙型或丙型肝炎病毒感染者尚未接受筛查,也不知道自己感染了病毒;大多数国家,特别是发展中国家,没有预防和控制病毒性肝炎的国家计划。有效的丙型肝炎新治疗方法的出现是一种变革因素,使人们能够考虑消除这种疾病和加速病毒性肝炎总体控制的可行性。这些事实促使病毒性肝炎预防委员会(VHPB)于2015年6月8日至9日在伦敦组织了一次会议,讨论中低收入国家病毒性肝炎预防和治疗的创新资金来源。会议的主要重点是概述目前在中低收入国家控制病毒性肝炎的卫生系统;确定如何加强这些国家对病毒性肝炎预防和控制规划的政治承诺和财政可持续性;确定潜在的资助者并探索新的筹资机制;讨论关于资助其他疾病规划的经验教训;调查如何说服和激励决策者为中低收入国家的病毒性肝炎规划提供资金;为改善中低收入国家获得负担得起的病毒性肝炎筛查和治疗提供备选方案;并列出包括政府、双边和多边组织、非传统捐助者、开发银行、基金会和商业金融机构在内的捐助者所需提供资金的承诺。为改善中低收入国家的病毒性肝炎预防和治疗,参与肝炎和融资的专家确定了最迫切的需求。必须改进关于疾病负担的数据。应起草和实施全面的肝炎政策和战略,并改进现有战略和政策,以增加获得治疗和预防的机会。应该产生强烈的政治意愿和领导,确定潜在的伙伴,建立伙伴关系。必须研究潜在的资助者和筹资机制。本次会议的成果被纳入了一个乙肝和丙肝规划项目,该项目旨在调查创造性融资解决方案,以扩大中低收入国家乙肝和丙肝筛查和其他预防服务、治疗和护理的获取和提供。该报告可在www.vhpb.org上查阅。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries: a roundtable meeting report.

Hepatitis B is preventable and hepatitis C is treatable even if still at a high cost; most people who are infected with hepatitis B or C virus have not been screened yet and are unaware of their infections; and most countries, especially developing countries, do not have a national plan to prevent and control viral hepatitis. The advent of effective new treatments for hepatitis C has been an agent of change, allowing consideration of the feasibility of eliminating that disease and accelerating the control of viral hepatitis generally. These facts inspired the Viral Hepatitis Prevention Board (VHPB) to organize a meeting in London (8-9 June 2015) on innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries. The main focus of the meeting was to provide an overview of current health systems controlling viral hepatitis in low- and middle-income countries (LMICs); to identify ways to increase political commitment and financial sustainability of viral hepatitis prevention and control programmes in such countries; to identify potential funders and explore new funding mechanisms; to discuss lessons learnt about funding other disease programmes; to investigate how to convince and motivate decision-makers to fund viral hepatitis programmes in LMICs; to provide options for improving access to affordable screening and treatment of viral hepatitis in LMICs; and to list the commitments required for funding by donors, including governments, bilateral and multilateral organizations, non-traditional donors, development banks, foundations, and commercial financial institutions. To improve viral hepatitis prevention and treatment in LMICs participating hepatitis and financing experts identified the most urgent needs. Data on burden of disease must be improved. Comprehensive hepatitis policies and strategies should be drafted and implemented, and existing strategies and policies improved to increase access to treatment and prevention. Strong political will and leadership should be generated, potential partners identified and partnerships created. Potential funders and funding mechanisms have to be researched. The outcome of this meeting was integrated in a VHPB project to investigate creative financing solutions to expand access to and provision of screening and other preventive services, treatment and care of hepatitis B and C in LMICs. The report is available on www.vhpb.org.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Correlates of hepatitis B awareness and disease-specific knowledge among pregnant women in Northern and Central Uganda: a cross-sectional study. Correction to: Hepatology, Medicine and Policy: Articles with DOIs 10.1186/s41124-016-0014-8, 10.1186/s41124-016-0013-9 and 10.1186/s41124-016-0012-x. Strategies for achieving viral hepatitis C micro-elimination in the Netherlands. Erratum: Publisher Correction to Hepatology, Medicine and Policy: Articles with DOIs 10.1186/s41124-017-0024-1, 10.1186/s41124-017-0025-0, 10.1186/s41124-017-0026-z and 10.1186/s41124-017-0027-y. Seroprevalence of hepatitis B and C in Nepal: a systematic review (1973-2017).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1